Telaprevir and Vaqta Pediatric

• Generic Name: telaprevir
• Dosage Forms: n.a.
• Other Brand Names: Incivek

Telaprevir is used in combination with injectable peginterferon alfa (Pegasys®, Pegintron®) and ribavirin (Copegus®, Rebetol®) to treat chronic hepatitis C infection. These medicines are used in patients with liver disease (including cirrhosis) who have not been treated before or who have received other medicines that did not work well. Telaprevir is an antiviral agent.

Telaprevir was available only with your doctor's prescription.

Telaprevir was withdrawn from the United States market on October 16, 2014.

• Generic Name: hepatitis a pediatric vaccine
• Dosage Forms: n.a.
• Other Brand Names: Havrix Pediatric, Vaqta Pediatric

Hepatitis is a serious disease caused by a virus. Hepatitis causes inflammation of the liver, vomiting, and jaundice (yellowing of the skin or eyes). Hepatitis can lead to liver cancer, cirrhosis, or death.

Hepatitis A is spread through contact with the stool (bowel movements) of a person infected with the hepatitis A virus. This usually occurs by eating food or drinking water that has become contaminated as a result of handling by an infected person.

The Vaqta Pediatric is used to help prevent this disease in children.

This vaccine works by exposing your child to a small amount of the virus, which causes the body to develop immunity to the disease. This vaccine will not treat an active infection that has already developed in the body.

Vaccination with Vaqta Pediatric is recommended for all children who are 12 months of age or older. This vaccine is also recommended in children who travel to certain areas of the world where hepatitis A is a common disease.

Other risk factors for hepatitis in children include: receiving treatment for hemophilia or other bleeding disorders, or being in an area where there has been an outbreak of hepatitis A.

Like any vaccine, the Vaqta Pediatric may not provide protection from disease in every person.